

Report Part Title: Methods

Report Title: Clinical management of COVID-19

Report Subtitle: Interim guidance

Report Author(s): World Health Organization

Published by: World Health Organization (2020)

Stable URL: <https://www.jstor.org/stable/resrep27972.4>

JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org.

Your use of the JSTOR archive indicates your acceptance of the Terms & Conditions of Use, available at <https://about.jstor.org/terms>



JSTOR

World Health Organization is collaborating with JSTOR to digitize, preserve and extend access to this content.

Foreword

The *Strategic preparedness and response plan* outlines WHO's strategic objectives to end the COVID-19 pandemic and assists national stakeholders with developing a structured approach to their response. The World Health Organization's (WHO) main objectives for COVID-19 are to:

- 1) slow and stop transmission;
- 2) provide optimized care for all patients; and
- 3) minimize the impact of the epidemic on health systems, social services and economic activity.

To achieve these objectives, the WHO *Operational considerations for case management of COVID-19 in health facility and community* describes key actions that should be taken in each transmission scenario: no cases; sporadic cases; clusters of cases; and community transmission, in order to enable timely surge of clinical and public health operations.

This guidance, *Clinical management of COVID-19*, is based on the above strategic priorities, and is intended for clinicians involved in the care of patients with suspected or confirmed COVID-19. It is not meant to replace clinical judgment or specialist consultation but rather to strengthen frontline clinical management. Considerations for special and vulnerable populations, such as paediatric patients, older people and pregnant women, are highlighted throughout the text.

In this document we refer to the **COVID-19 care pathway (Appendix 1)**. This describes a coordinated and multidisciplinary care pathway that a patient enters after s/he is **screened to be a suspect COVID-19 case**, and follows the continuum of their care until release from the pathway. The objective is to ensure delivery of safe and quality care while stopping onwards viral transmission. All others enter the health system in the non-COVID-19 pathway. For the most up-to-date technical guidance related to the COVID-19 response, visit WHO Country & Technical Guidance (1).

Methods

The original version of this document was developed in consultation with the International Forum for Acute Care Trialists (InFACT), International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and the Surviving Sepsis Campaign. This is the third edition (version 1.3) of this document, which was originally adapted from *Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected* (WHO, 2019).

For the development of the third version of the COVID-19 clinical guidance, we assembled a formal Guideline Development Group (GDG) comprising individuals with broad expertise spanning multiple specialties and all regions. Confidentiality and declarations of interest were collected and reviewed and no conflict of interest was identified.

Because of the accelerated timeline and very broad scope of the guideline, it was not feasible to undertake a formal GRADE process (PICO questions; systematic reviews; formal documentation of values and preferences and incorporation of considerations of costs, resources, and feasibility). The topics for consideration originated in the WHO interim guidance for MERS, but for COVID-19 were greatly expanded to reflect the full spectrum of illness, from screening to rehabilitation. Published evidence was synthesized under the coordination of the Science Division in rapid systematic reviews, which were pre-circulated to the GDG. The WHO Steering Committee initially drafted the recommendations about interventions based on these reviews and input from expert clinicians participating in twice-weekly clinical network teleconferences. The GDG held four virtual meetings via

teleconference (total of 12 hours) to discuss all previous and new recommendations. Suggested revisions were incorporated into the guidance. Consensus was achieved for all recommendations presented in the final version.

The direction and strength of recommendations are presented using symbols rather than formal GRADE terminology (strong and conditional recommendations with grading of certainty of evidence, or best practice statements).



The GREEN symbol denotes a strong recommendation or a best practice statement in favour of an intervention.



The RED symbol denotes a recommendation or a best practice statement against an intervention.



The YELLOW symbol denotes a conditional recommendation in favour of an intervention, or a recommendation where special care is required in implementation.

This guidance has been significantly expanded to meet the needs of front-line clinicians caring for patients with COVID-19 to ensure quality care. The following sections are entirely new: COVID-19 care pathway, treatment of acute and chronic infections, management of neurological and mental manifestations, noncommunicable diseases, rehabilitation, palliative care, ethical principles, and reporting of death. The remaining sections have been substantially expanded. Though not intended to be an exhaustive list, the following bullets highlight some key changes:

- Discontinue transmission-based precautions (including isolation) and release from the COVID-19 care pathway: **For symptomatic patients: 10 days after symptom onset, plus at least 3 days without symptoms (without fever and respiratory symptoms).**
- Treatment of acute co-infections: **For suspected or confirmed mild COVID-19, against the use of antibiotic therapy or prophylaxis. For suspected or confirmed moderate COVID-19, that antibiotics should not be prescribed unless there is clinical suspicion of a bacterial infection.**
- Prevention of complications: **In patients (adults and adolescents) hospitalized with COVID-19, use pharmacological prophylaxis, such as low molecular weight heparin (e.g. enoxaparin), according to local and international standards, to prevent venous thromboembolism, when not contraindicated. For those with contraindications, use mechanical prophylaxis (intermittent pneumatic compression devices).**

And, importantly, key previous recommendations that remain are:

- Antivirals, immunomodulators and other adjunctive therapies: **WHO recommends that the listed drugs not be administered as treatment or prophylaxis for COVID-19, outside the context of clinical trials.**
- Corticosteroids and COVID-19: **WHO recommends against the routine use of systemic corticosteroids for treatment of viral pneumonia.**

Developed by a multidisciplinary panel of health care providers with experience in the clinical management of patients with COVID-19 and other viral infections, including severe acute respiratory virus (SARS) and Middle East respiratory virus (MERS), as well as sepsis and

acute respiratory distress syndrome (ARDS), this guidance should serve as a foundation for optimized clinical care to ensure the best possible chance for survival. The guidance stresses the importance of using investigational therapeutic interventions as part of randomized controlled trials (RCTs) (2-4). For queries, please email: EDCARN@who.int with "COVID-19 clinical question" in the subject line.

Acknowledgements

WHO: Janet V Diaz (Lead), April Baller, Anshu Banerjee, Silvia Bertagnolio, Mercedes Bonet, Andrea Bosman, Marie-Charlotte Bousseau, Maurice Bucagu, Neerja Chowdhary, Jane Cunningham, Meg Doherty, Tarun Dua, Nathan Ford, Laurence Grummer-Strawn, Fahmy Hanna, Benedikt Huttner, Ernesto Jaramillo, Maria Van Kerkhove, Caron Kim, Kavitha Kolappa, Teresa Kortz, Ornella Lincetto, Jody-Ann Mills, Lorenzo Moja, Susan Norris, Olufemi Oladapo, Peter Olumese, Mark van Ommeren, Martina Penazzato, Anayda Portela, Andreas Reis, Pryanka Relan, Lisa Rogers, Nigel Rollins, Ingrid Smith, Howard Sobel, Maria Pura Solon, Yuka Sumi, Anna Thorson, Kavita Trivedi, Marco Vitoria, Prinzo Weise, Wilson Were, Matteo Zignol.

UNICEF: Maya Aarii.

Guideline Development Group members: Neill Adhikari, Sunnybrook Health Sciences Centre and University of Toronto; John Adabie Appiah, Senior Specialist, Paediatric Critical Care and Head of Paediatric Intensive Care Unit of the Komfo Anokye Teaching Hospital, Ghana; Abdullah Balkhair, Head of Infectious Diseases Unit and Infection Control Department, Sultan Qaboos University, Oman; Florence Baingana, Research Fellow, Makerere University, Kampala, Uganda; Corrado Barbui, WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, University of Verona, Italy; Lucille Blumberg, National Institute for Communicable Diseases (NICD), South Africa; Bin Cao, China-Japan Friendship Hospital, Capital Medical University, Beijing, China; Maurizio Cecconi, Head of Department Anesthesia and Intensive Care Units, Humanitas Research Hospital, Milan, Italy; Bronwen Connolly, Queen's University Belfast, UK; Vu Quoc Dat, Department of Infectious Diseases, Hanoi Medical University, Viet Nam; Jake Dunning, Head of Emerging Infections and Zoonoses, Public Health England, UK; Rob Fowler, University of Toronto, Canada; Heike Geduld, African Federation for Emergency Medicine, Cape Town, South Africa; Charles Gomersall, Chinese University of Hong Kong, Hong Kong SAR, China; Rumina Hasan, Professor, Department of Pathology and Laboratory Medicine, Aga Khan University, Pakistan, and Honorary Professor, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, UK; Manai Hela, Emergency Medical Service Tunis, Tunisia; David S Hui, Chairman of the Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, China; Yae-Jean Kim, Sungkyunkwan University, Samsung Medical Center, Republic of Korea; Niranjana Kissoon, Professor in Critical Care, University of British Columbia and BC Children's Hospital, Vancouver, Canada; Arthur Kwizera, Department of Anaesthesia and Critical Care, Makerere University, Kampala, Uganda; Pisake Lumbiganon, Director WHO Collaborating Centre for Research Synthesis in Reproductive Health, Faculty of Medicine, Khon Kaen University, Thailand; Flavia Machado, Anesthesiology, Pain and Intensive Care Department, Federal University of São Paulo, Brazil; Srinivas Murthy, Associate Professor, University of British Columbia, Vancouver, Canada; Saniya Sabzwari, Aga Khan University Hospital, Karachi, Pakistan; Rohit Sarin, Director, National Center of Excellence Supranational TB Reference Laboratory, New Delhi, India; Yinzhang Shen, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China;